For Q4 2025, Dyne reported a net loss of 111955000, driven by research and development expenses of 95431000 and general and administrative expenses of 20698000. The company ended the year with 1110562000 in cash, cash equivalents and marketable securities, supporting runway into Q1 2028.

Dyne Therapeutics reported a net loss of $115.4 million for the first quarter of 2025. The company is advancing its lead programs, DYNE-101 and DYNE-251, towards potential U.S. Accelerated Approval submissions in 2026, and strengthened its leadership team in preparation for potential regulatory filings and commercial launches.

Dyne Therapeutics reported a net loss of $89.5 million for Q4 2024. The company's cash, cash equivalents, and marketable securities totaled $642.3 million as of December 31, 2024, which, combined with proceeds from a Q1 2025 stock sale, is expected to fund operations into the second half of 2026.

Dyne Therapeutics reported positive progress in their ACHIEVE and DELIVER trials, with IND clearance for DYNE-101. The company is enrolling a registrational cohort of DYNE-251 DELIVER trial in DMD and anticipates reporting new data from the ACHIEVE trial in early January 2025. The company's cash position is expected to fund operations into the second half of 2026.

Dyne Therapeutics reported positive clinical data from its ACHIEVE and DELIVER trials, showing meaningful impact on key biomarkers and functional improvements. The company also strengthened its balance sheet with a $374 million public offering, extending the projected cash runway into the second half of 2026.

Dyne Therapeutics reported a net loss of $65.6 million for the first quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $453.5 million as of March 31, 2024, which are anticipated to fund operations through 2025.

Dyne Therapeutics reported positive initial clinical data from ACHIEVE and DELIVER trials, demonstrating proof-of-concept for their FORCE™ platform. They strengthened their balance sheet with a $345 million public offering, extending their cash runway through 2025. The company is focused on optimizing dose and dose regimen in 2024 and plans to provide updates from both trials in the second half of the year.

Dyne Therapeutics reported progress in their ACHIEVE and DELIVER trials, with favorable safety profiles supporting dose escalation. Initial data from both trials, including biomarker and functional outcome data, is expected in early January 2024. The company's cash, cash equivalents, and marketable securities were $157.8 million as of September 30, 2023, expected to fund operations through 2024. The net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share.

Dyne Therapeutics reported a net loss of $64.9 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities were $207.7 million as of June 30, 2023, which is anticipated to fund operations through 2024. Enrollment continues in ACHIEVE and DELIVER trials and initial data is expected in the second half of 2023.

Dyne Therapeutics reported progress in their ACHIEVE and DELIVER trials with initial data expected in the second half of 2023. The company's cash, cash equivalents and marketable securities are anticipated to fund operations through 2024.

Dyne Therapeutics reported a net loss of $38.8 million for the quarter ended December 31, 2022, with cash, cash equivalents, and marketable securities totaling $256.0 million, expected to fund operations through 2024.

Dyne Therapeutics reported a net loss of $41.4 million for the third quarter of 2022. The company's cash, cash equivalents, and marketable securities were $248.1 million as of September 30, 2022, which is anticipated to fund operations through 2024. Clinical trials for DYNE-101 and DYNE-251 are underway with data anticipated in the second half of 2023.

Dyne Therapeutics reported a net loss of $52.3 million for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $291.8 million as of June 30, 2022, which is anticipated to fund operations into the second half of 2024. They are on track for mid-2022 for initiation of patient dosing in multiple ascending dose clinical trials for DYNE-251 in DMD and DYNE-101 in DM1.

Dyne Therapeutics reported a net loss of $35.6 million for the first quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $323.2 million as of March 31, 2022.

Dyne Therapeutics reported a net loss of $51.8 million for Q4 2021. The company's cash, cash equivalents, and marketable securities totaled $376.6 million as of December 31, 2021, expected to fund operations into the second half of 2024. The company is on track to submit its response to the FDA for DYNE-251 IND in DMD in the second quarter.

Dyne Therapeutics reported its third quarter 2021 financial results, highlighting progress in advancing its co-lead programs, DYNE-251 and DYNE-101, towards clinical trials, with IND submissions anticipated in Q4 2021 and Q1 2022, respectively. The company's cash, cash equivalents, and marketable securities were $407.5 million as of September 30, 2021.

Dyne Therapeutics reported a net loss of $30.0 million, or $0.58 per common share, for the second quarter of 2021. As of June 30, 2021, cash, cash equivalents and marketable securities were $435.6 million.

Dyne Therapeutics reported a net loss of $25.0 million for the first quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $483.1 million as of March 31, 2021, providing a cash runway expected into the second half of 2024. The company is on track to submit INDs for DM1, DMD and FSHD programs between the fourth quarter of 2021 and the fourth quarter of 2022.

Dyne Therapeutics reported a net loss of $28.6 million for Q4 2020. The company's cash, cash equivalents, and marketable securities totaled $345.3 million as of December 31, 2020. Research and development expenses were $22.1 million, and general and administrative expenses were $6.5 million for the quarter.

Dyne Therapeutics reported a net loss of $13.9 million for the third quarter of 2020, with cash and cash equivalents totaling $379.6 million. The company successfully completed its IPO, raising $267.7 million in gross proceeds, and a Series B financing, raising $115.7 million.